Bottom line
How much do PBE and BIB overlap?
31% of their top holdings overlap by weight. 9 securities appear in both funds' top 25, making up 38.7% of PBE's assets and 23.9% of BIB's. They share a meaningful core but differ in the rest of the portfolio.
BIB holds far more positions (267 vs 33), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings PBE and BIB have in common
| Holding | % of PBE | % of BIB | Overlap |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 5.47% | 3.21% | 3.21% |
| Amgen Inc. | 5.22% | 4.48% | 4.48% |
| Vertex Pharmaceuticals Inc. | 4.99% | 4.65% | 4.65% |
| Biogen Inc. | 4.79% | 1.44% | 1.44% |
| Gilead Sciences, Inc. | 4.43% | 4.66% | 4.43% |
| United Therapeutics Corp. | 4.08% | 1.22% | 1.22% |
| Illumina, Inc. | 3.51% | 1.25% | 1.25% |
| Alnylam Pharmaceuticals, Inc. | 3.17% | 2.01% | 2.01% |
| Incyte Corp. | 3.06% | 0.97% | 0.97% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PBE
- Invesco Private Prime Fund — 12.89%
- CareDx, Inc. — 5.04%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Bio-Techne Corp. — 3.73%
- Protagonist Therapeutics, Inc. — 3.40%
- Vericel Corp. — 3.27%
- Repligen Corp. — 3.04%
- Acadia Pharmaceuticals Inc. — 3.02%
- Halozyme Therapeutics, Inc. — 2.98%
- Qiagen N.V. — 2.89%
- BioMarin Pharmaceutical Inc. — 2.82%
- Neurocrine Biosciences, Inc. — 2.66%
- Exelixis, Inc. — 2.64%
- BioCryst Pharmaceuticals, Inc. — 2.63%
Only in BIB
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- N/a — 3.94%
- N/a — 3.26%
- N/a — 2.62%
- Revolution Medicines, Inc. — 1.57%
- Repurchase Agreement — 1.28%
- Royalty Pharma plc — 1.20%
- Argenx SE — 1.19%
- N/a — 1.18%
- Insmed, Inc. — 1.16%
- Roivant Sciences Ltd. — 1.08%
- Viatris, Inc. — 0.94%
- Moderna, Inc. — 0.94%
- Guardant Health, Inc. — 0.85%
Asset mix
| Asset type | PBE | BIB |
|---|---|---|
| Stocks | 100.1% | 63.0% |
| Cash & short-term funds | 17.9% | 0.8% |
| Equity derivatives | — | 16.0% |
| Other | — | 6.8% |
| Repurchase agreements | — | 3.1% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Country mix
| Country | PBE | BIB |
|---|---|---|
| US | 108.6% | 79.8% |
| GB | 4.9% | 1.7% |
| NL | 2.9% | 1.6% |
| KY | 1.6% | 0.4% |
| IE | — | 1.2% |
| BM | — | 1.1% |
| FR | — | 1.0% |
| DK | — | 0.8% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Check another pair
FAQ
How much do PBE and BIB overlap?
What stocks do PBE and BIB have in common?
Should I own both PBE and BIB?
Which holds more stocks, PBE or BIB?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.